Sanofi News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

31.07.18	Sanofi Q2 Profit Down 26%; Narrows FY18 Business EPS View - Quick Facts (RTTNews)
29.06.18	Sanofi: CHMP Recommends Approval Of Cablivi For Rare Blood Disorder (RTTNews)
25.06.18	Sanofi Reports Positive Results From Study Comparing Insulin Toujeo To Degludec (RTTNews)
25.06.18	Evotec Gets EUR 3 Mln Beta Cell Therapy Milestone Payment From Sanofi (RTTNews)
19.06.18	Sanofi Closes Acquisition Of Ablynx (RTTNews)
13.06.18	How Ameritech Financial Can Help Women and Minorities With Student Loans (PR Newswire)
13.06.18	Les employeurs canadiens sous-estiment la proportion de leur effectif qui est atteint d'une maladie chronique et son incidence (PR Newswire)
13.06.18	Canadian employers underestimate the proportion of their workforce with a chronic condition and its impact (PR Newswire)
13.06.18	Canadian employers underestimate the proportion of their workforce with a chronic condition and its impact (PR Newswire)
11.06.18	Translate Bio, Sanofi Pasteur Join To Advance MRNA Vaccines - Quick Facts (RTTNews)
04.06.18	New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma (PR Newswire)
22.05.18	Lexicon Pharma: FDA To Review Sanofi's Filing For Zynquista - Quick Facts (RTTNews)
22.05.18	FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes (PR Newswire)
21.05.18	New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma (PR Newswire)
16.05.18	Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis (PR Newswire)
16.05.18	Regeneron, Sanofi: Phase 3 Dupixent Trial Meets Primary, Key Secondary Endpoints (RTTNews)
07.05.18	Building Safety Month Is Right Time To Assess Lightning's Dangers (PR Newswire)
02.05.18	DocPanel Announces Partnership with the University of Southern California Keck School of Medicine (PR Newswire)
01.05.18	Sanofi, Renegeron To Lower Net Price Of Praluent Injection - Quick Facts (RTTNews)
01.05.18	Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access for Express Scripts patients (PR Newswire)
01.05.18	INGN Soars On Revised Outlook, MRK Faces FDA In Sep., KPTI Taken By STORM (RTTNews)
30.04.18	Regeneron And Sanofi Say FDA Accepts Priority Review BLA For Cemiplimab (RTTNews)
30.04.18	FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma (PR Newswire)
27.04.18	Sanofi: First-quarter 2018 Business EPS up 1.4% at CER (PR Newswire)
27.04.18	Sanofi Q1 Profit Drops; Backs 2018 Business EPS View (RTTNews)
24.04.18	Sanofi Names Roche's John Reed Head Of Global R&D, Succeeding Elias Zerhouni (RTTNews)
18.04.18	ARTiFACTS and Blockchain in Healthcare Today Partner to Expand Use of Blockchain in Scholarly Publishing (PR Newswire)
12.04.18	Sanofi va investir 350 millions d'euros dans une unité de production de vaccins au Canada (PR Newswire)
12.04.18	Sanofi to invest €350 million in Canadian vaccine facility (PR Newswire)
12.04.18	Sanofi to invest €350 million in Canadian vaccine facility (PR Newswire)
12.04.18	New tools, support and information on insulin use now available to Canadians living with Type 2 diabetes aiming to maintain healthy blood glucose levels (PR Newswire)
12.04.18	New tools, support and information on insulin use now available to Canadians living with Type 2 diabetes aiming to maintain healthy blood glucose levels (PR Newswire)
12.04.18	Des moyens innovants et de nouvelles informations sur l'utilisation de l'insuline sont maintenant offerts aux Canadiens vivant avec le diabète de type 2 qui essaient d'atteindre une glycémie saine (PR Newswire)
06.04.18	A Glance At Potential Therapies For Sickle Cell Disease (RTTNews)
05.04.18	Sanofi Announces Its Insulins VALyou Savings Program - Quick Facts (RTTNews)
05.04.18	New Sanofi insulin savings program aims to lower out-of-pocket costs for people living with diabetes (PR Newswire)
04.04.18	Strongbow Hard Ciders Invites America To Drink Rosé The UK Way (PR Newswire)
03.04.18	Will These Drugs Reach Blockbuster Status? (RTTNews)
03.04.18	Regeneron And Sanofi Say EMA Accepts For Review Application For DUPIXEN (RTTNews)
29.03.18	Sanofi: EMA To Review Regulatory Submission For Sotagliflozin - Quick Facts (RTTNews)
27.03.18	Sanofi: FDA Approves Toujeo Max SoloStar Pen - Quick Facts (RTTNews)
27.03.18	FDA approves Toujeo® Max SoloStar® (PR Newswire)
15.03.18	Sanofi Prices EUR 8 Bln Of Bond Issues - Quick Facts (RTTNews)
12.03.18	SVRA Disappoints, SNY/REGN's Praluent Price To Be Cut, OBSV On Watch (RTTNews)
11.03.18	Praluent® (alirocumab) a significativement réduit le risque d'événements cardiovasculaires chez des patients à risque élevé, et a été associé à une réduction du taux de mortalité (PR Newswire)
11.03.18	Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate (PR Newswire)
11.03.18	Praluent® (alirocumab) significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate (PR Newswire)
10.03.18	Regeneron, Sanofi To Cut Heart Drug's Price; Say Praluent Lowers Risk Of Death (RTTNews)
10.03.18	Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need (PR Newswire)
10.03.18	Praluent® (alirocumab) Injection significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

17.10.24		Sanofi-Aktie wenig bewegt: Sorgen der Regierung gegen Opella-Teilverkauf sollen beschwichtigt werden
04.10.24		Sanofi-Aktie gefragt: Recordati erwirbt Sanofi Enjaymo-Rechte für eine knappe Milliarde Dollar
12.09.24		Sanofi startet Kooperation zur Bekämpfung seltener Krebserkrankungen - Aktie gibt nach
11.09.24		Sanofi mit Studienerfolg: Dupixent hilft bei Hautkrankheiten - Aktie dennoch tiefer
02.09.24		Sanofi-Medikament Tolebrutinib zeigt gute Ergebnisse - Sanofi-Aktionäre begeistert
04.07.24		Sanofi-Aktie kaum bewegt: Bain und Cinven ziehen wohl Übernahme von Sanofis Consumer-Sparte in Betracht
03.07.24		Sanofi-Aktie moderat im Plus: Dupixent von Sanofi erhält EU-Zulassung für COPD-Behandlung
26.06.24		Sanofi-Aktie im Minus: Verkauf von Consumer Health steht offenbar in den Startlöchern - möglicher IPO

17.10.24

Sanofi-Aktie wenig bewegt: Sorgen der Regierung gegen Opella-Teilverkauf sollen beschwichtigt werden

04.10.24

Sanofi-Aktie gefragt: Recordati erwirbt Sanofi Enjaymo-Rechte für eine knappe Milliarde Dollar

12.09.24

Sanofi startet Kooperation zur Bekämpfung seltener Krebserkrankungen - Aktie gibt nach

11.09.24

Sanofi mit Studienerfolg: Dupixent hilft bei Hautkrankheiten - Aktie dennoch tiefer

02.09.24

Sanofi-Medikament Tolebrutinib zeigt gute Ergebnisse - Sanofi-Aktionäre begeistert

04.07.24

Sanofi-Aktie kaum bewegt: Bain und Cinven ziehen wohl Übernahme von Sanofis Consumer-Sparte in Betracht